The “Australia and New Zealand prothrombin complex concentrate market” size is expected to experience considerable growth by reaching USD 40.4 million by 2027 while exhibiting a CAGR of 10.9% between 2020 and 2027. This growth is attributable to the increasing consumption of Vitamin K antagonists such as warfarin that is likely to surge the demand for advanced prothrombin complex concentrates in Australia and New Zealand. This information is published by Fortune Business Insights in its latest report, titled, “Australia and New Zealand Prothrombin Complex Concentrate Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Factor Deficiency and Congenital Coagulation Factor Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027.” The report further observes that the market stood at USD 17.8 million in 2019.
The COVID-19 pandemic has affected several economies that are facing unprecedented loss. Owing to the lockdown announced by the government agencies and reduced labor force, several industries have been on a standstill with limited operational activities. However, a proactive combined effort from the government and other industries is anticipated to bring the economy back on track and aid in the industrial activities returning to pre-pandemic levels.
Prothrombin complex concentrate (PCC) is manufactured after the removal of factor XI and antithrombin through a process of ion-exchange chromatography from the cryoprecipitate supernatant of large plasma pools. These concentrates are extensively used to treat and further prevent bleeding in the case of hemophilia B if a pure factor IX is not present.
Major Australia and New Zealand Prothrombin Complex Concentrate Market Key players covered in the report include:
- CSL Limited (Melbourne, Australia)
- Grifols, S.A. (Barcelona, Spain)
- Octapharma AG (Lachen, Switzerland)
- Kedrion S.p.A (Lucca, Italy)
- Sanquin (Amsterdam, The Netherlands)
- Takeda Pharmaceutical Company Limited (Mumbai, India)
- Other Prominent Players
Get Request a Sample Copy of the Australia and New Zealand Prothrombin Complex Concentrate Report:
Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers and acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.
It offers figurative estimations for upcoming years on the basis of the recent developments and historic data. For gathering information and estimating revenue for all segments, researchers have used top-down and bottom-up approaches. On the basis of data collected from primary and secondary research and trusted data sources the report will help both existing and new aspirants for market to figure out and study the market’s needs, market size, and competition.
Australia and New Zealand Prothrombin Complex Concentrate Market Analysis 2021:
Increasing Consumption of Vitamin K Antagonists to Surge Demand
As per an article published by The National Center for Biotechnology Information (NCBI), it is anticipated that at least 1%-2% of the total population takes warfarin therapy. Owing to its affordability, warfarin is widely consumed, however, this anticoagulation agent may lead to fatal bleeding disorders due to over-dependency. Therefore, this is expected to boost the demand for advanced prothrombin complex concentrates that aid in effective treatment and prevention of bleeding disorders. Moreover, supportive government initiatives to promote awareness regarding the adoption of PCC is expected to contribute to the Australia and New Zealand prothrombin complex concentrate market growth in the forthcoming years.
Australia and New Zealand Generated USD 17.8 Million in terms of Revenue in 2019
The increasing number of specialty clinics and the growing number of geriatric population is expected to boost the Australia and New Zealand prothrombin complex concentrate market share in the forthcoming years.
Contract Signing by Major Companies to Intensify Industry Competition
The market for Australia and New Zealand prothrombin complex concentrate is fragmented by the presence of prominent companies focusing on signing contracts with government agencies or other companies to expand their product portfolio. Additionally, other key players are striving to maintain their presence and gain a competitive edge over their rivals by adopting several organic and inorganic strategies that will favor the market growth.
April 2018 – Sanquin announced its multi-year agreement with Abbott, a leading company in transfusion medicine. Under the agreement, the company will supply primary serological equipment and consumables that further includes Abbott’s Alinity system for blood and plasma screening.
Table of Content:
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Epidemiology of Coagulation Factor Deficiency in Australia and New Zealand
- Recent Industry Developments – Partnerships, Mergers & Acquisitions
- Regulatory Scenario – For Key Countries
- Analysis in Relation to Alternatives to PCC
- PCC Market: Reimbursement Scenario & Key Industry Trends
- Impact of COVID-19 on PCC Market
- Australia & New Zealand Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Product – By Value (US$, Mn)
- 3-factor PCC
- 4-factor PCC
- Market Analysis, Insights and Forecast – By Application-By Value (US$, Mn)
- Acquired Coagulation Factor Deficiency
- Congenital Coagulation Factor Deficiency
- Market Analysis, Insights and Forecast – By End User – By Value (US$, Mn)
- Ambulatory Surgical Centers
- Competitive Analysis
- Key Industry Developments
- Global Market Share Analysis (2019)
- Competition Dashboard
- Comparative Analysis – Major Players
- Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (based on availability))
- CSL Limited
- Grifols SA
- Octapharma AG
- Kedrion S.p.A
- Shire (Takeda Pharmaceutical Company Limited)
- Other Players
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune -411045, Maharashtra, India.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Related Reports :